Cefditoren pivoxil: A new oral cephalosporin for skin, soft tissue and respiratory tract infections;Cefditoren pivoxilo: Una nueva cefalosporina oral para infecciones de vías respiratorias y de piel y tejidos blandos

Revista Espanola de Quimioterapia

Volumn 19, Issue 3, 2006, Pages 231-246

  Hernández Martín, Julia ^a   Roma E ^a   Salavert, M ^a   Domenech L ^a   Poveda, J L ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Bronchitis; Cefditoren pivoxil; Cephalosporins; Pharyngeal tonsillitis; Pneumonia; Sinusitis

Indexed keywords

ALUMINUM HYDROXIDE; BETA LACTAMASE; CEFDITOREN; CEFDITOREN PIVOXIL; CEFIXIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIMETIDINE; FAMOTIDINE; MAGALDRATE; MAGNESIUM CARBONATE; MAGNESIUM HYDROXIDE; MAGNESIUM OXIDE; METICILLIN; NIZATIDINE; PENICILLIN G; PROBENECID; RANITIDINE;

ABDOMINAL PAIN; ACNE; ALBUMINURIA; ALOPECIA; AMNESIA; ANAEROBIC BACTERIUM; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; ASTHMA; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COORDINATION DISORDER; COST EFFECTIVENESS ANALYSIS; DEHYDRATION; DEMENTIA; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DYSPEPSIA; DYSURIA; ECZEMA; EOSINOPHILIA; ERECTILE DYSFUNCTION; EUPHORIA; EYE PAIN; FEVER; FLATULENCE; GASTROINTESTINAL HEMORRHAGE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE TYPE A; HALLUCINATION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEMOLYTIC ANEMIA; HEMORRHAGIC COLITIS; HERPES; HUMAN; HYDROLYSIS; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOKALEMIA; HYPOPROTEINEMIA; INCONTINENCE; INSOMNIA; KIDNEY PAIN; LEUKOPENIA; LEUKORRHEA; LIBIDO DISORDER; LIVER DYSFUNCTION; LYMPHADENOPATHY; MASTALGIA; MAXIMUM ALLOWABLE CONCENTRATION; MENINGITIS; MENORRHAGIA; MORAXELLA CATARRHALIS; MOUTH ULCER; MUSCLE HYPERTONIA; MYALGIA; NAUSEA; NEWBORN EXFOLIATIVE DERMATITIS; ORTHOSTATIC HYPOTENSION; PHARYNGITIS; PHOTOSENSITIVITY; POLYURIA; PRURITUS; RASH; RESPIRATORY TRACT INFECTION; REVIEW; RHINITIS; SIDE EFFECT; SINUSITIS; SKIN INFECTION; SOFT TISSUE INFECTION; SOMNOLENCE; STOMATITIS; STREPTOCOCCUS PNEUMONIAE; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOCYTOSIS; THRUSH; TINNITUS; TONGUE DISEASE; TREMOR; ULCERATIVE COLITIS; URINARY TRACT INFECTION; URTICARIA; VAGINA CANDIDIASIS; VAGINITIS; VOMITING;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CLINICAL TRIALS; HUMANS; RESPIRATORY TRACT INFECTIONS; SKIN DISEASES, INFECTIOUS; SOFT TISSUE INFECTIONS;

EID: 33750906744     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Giménez, M.J., Gómez-Lus, M.L., Valdés, L., Aguilar, L. Situación de la cefalosporina oral de tercera generación cefditoreno pivoxil en el tratamiento de la infección comunitaria del adulto. Rev Esp Quimioterap 2005; 18: 210-216.
2. Zinner, S.H. The search for new antimicrobials: Why we need new options. Expert Rev Anti Infect Ther 2005; 3: 907-913.
3. Wellington, K., Curran, M. Cefditoren pivoxil. A review of its use in the treatment of bacterial infections. Drugs 2004; 64: 2597-2618.
4. Ficha técnica Meiact® (Laboratories Tedec-Meiji).
5. Martin, S.I., Kaye, K.M. Beta-lactam antibiotics: Newer formulations and newer agents. Infect Dis Clin N Am. 2004; 18: 603-619.
6. Darkes, M.J., Plosker, G.L. Cefditoren pivoxil. Drugs 2002; 62: 319-336.
7. Jones, R.N., Biedenbach, D.J., Croco, M.A.T. y cols. In vitro evaluation of a novel orally administered cephalosporin (cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. Diagn Microbiol Infect Dis 1998; 31: 573-578.
8. Fuchs, P.C., Barry, A.L., Brown, S.D. Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to cefditoren, and provisional interpretive criteria. Diagn Microbiol Infect Dis 2000; 37: 265-269.
9. Karlowsky, J.A., Jones, M.E., Draghi, D.C. y cols. In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren. Diagn Microbiol Infect Dis 2002; 42: 59-64.
10. Alcaide, F., Linares, J., Pallarés, R. y cols. In vitro activities of 22 β-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob Agents Chemother 1995; 39: 2243-2247.
11. Chin, N.X., Zhang, Y.X., Neu, H.C. In vitro activity of a new cephalosporin ME-106 compared with other agents. Diagn Microbiol Infect Dis 1991; 14: 417-424.
12. Watanabe, Y., Hatano, K., Matsumoto, Y. y cols. In vitro antibacterial activity of FK041, a new orally active cephalosporin. J Antibiot (Tokyo) 1999; 52: 649-659.
13. Felmingham, D., Robbins, M.J., Ghosh, G. y cols. An in vitro characterization of cefditoren, a new oral cephalosporin. Drugs Exp Clin Res 1994; 20: 127-147.
14. Johnson, D.M., Biedenbach, D.J., Beach, M.L. y cols. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. Diagn Microbiol Infect Dis 2000; 37: 99-105.
15. Jones, R.N., Biedenbach, D.J., Johnson, D.M. Cefditoren activity against nearly 1000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods. Diagn Microbiol Infect Dis 2000; 37: 143-146.
16. Miyazaki, S., Miyazaki, Y., Tsuji, A. y cols. In vitro antibacterial activity of ME1207, a new oral cephalosporin. Antimicrob Agents Chemother 1991; 35: 1691-1694.
17. Cefditoren (Drug Evaluation Monographs). En: Klasco, R.K. (Ed.). DRUGDEX® System. Thomson MICROMEDEX, Vol. 122. Greenwood Village, Colorado (ed. Exp. 03/2005).
18. Soriano, F., Granizo, J.J., Coronel, P. y cols. Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European. The ARISE project. Int J Antimicrob Agents 2004; 23: 296-299.
19. XXXVII Congreso Nacional de la SEPAR. Tendencias actuales en el tratamiento de la infección respiratoria. Valencia, 2005.
20. Kuti, J.L., Quintiliani, R. Cefditoren pivoxil: A novel broad-spectrum oral cephalosporin. Formulary 2001; 36: 265-268 y 271-275.
21. Guay, D.R. Review of cefditoren, an advanced-generation, broad-spectrum oral cephalosporin. Clin Ther 2001; 23: 1924-1937.
22. Shiba, K., Maezawa, H., Yoshida, M. y cols. Effects of antacids on pharmacokinetics of cefditoren pivoxil and its metabolism in humans. Chemotherapy 1992; 40: 1310-1319.
23. Consejo General de Colegios Oficiales de Farmacéuticos. Medicamentos en embarazo, madres lactantes, niños y ancianos. Einsa, Madrid 1991.
24. Henry, D.C., Poling, T.L., Bettis, R.B., Hunt, B.J., Cyganowski, M., Horn, R.C. A double-blind, randomized study of cefditoren vs. cefuroxime for AECB. J Respir Dis 2001; 22: S69-S74.
25. Van Zyl, L. V., Le Roux, J.G., LaFata, J.A. y cols. Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: Results of a multicenter, prospective, randomized double-blind study. Clin Ther 2002; 24: 1840-1853.
26. Fogarty, C.M., Cyganowski, M., Palo, W.A., Hom, R.C., Craig, W.A. A comparison of cefditoren pivoxil and amoxicillin/clavunate in the treatment of community-acquired pneumonia: A multicenter, prospective, randomized, investigator-blinded, parallel-group study. Clin Ther 2002; 24: 1854-1870.
27. Bucko, A.D., Hunt, B.J., Kidd, S.L., Hom, R. Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections. Clin Ther 2002; 24: 1134-1147.
28. Tucker, R., Rhudy, J., Hunt, B. y cols. Safety and efficacy of cefditoren in acute exacerbation of chronic bronchitis (AEBC). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto 2000; Abst. 836.
29. Tedec-Meiji Farma, S.A. Efficacy of cefditoren-pivoxil compared to cefuroxime-axetil in patients with acute exacerbation of chronic bronchitis in adults. Data on file, 2001.
30. Rubio-Terrés, C., Dominguez-Gil, A. Análisis farmacoeconómico del tratamiento de pacientes con exacerbación aguda de la bronquitis crónica con cefditoren pivoxilo o cefuroxima axetilo. Pharmacoeconomics-Spanish Research Articles 2005; 2: 45-54.
31. Kardos, P., Grymbowski, T., Coronel, P. y cols. Efficacy of cefditorenpivoxil compared to cefuroxime-axetil in patients with acute exacerbation of chronic obstructive bronchitis in adults. Clinical Trial Report WIS-IL1 ME 1207/ME 303. Grunental/Tedec Meiji Farma/Laboratorios Andrómaco. 29 de marzo de 2001.
32. Dorca, J., Bello, S., Blanquer, J.M. y cols. The diagnosis and treatment of community-acquired pneumonia. SEPAR Sociedad Española de Neumología y Cirugía Torácica. Arch Bronconeumol 1997; 33: 240-246.
33. Álvarez-Sala, J.L., Kardos, P., Martínez-Beitrán, J. y cols. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob Agents Chemother 2006; 50: 1762-1767.
34. Boxer, G., DeBellis, R., Emerman, C. y cols. Community-acquired pneumonia (CAP): Evidence-based antibiotic selection and outcome-effective patient management. Disponible en: http://www.antibiotic-consult.com.
35. Epstein, B.J., Gums, J.G. Optimal pharmacological therapy for community-acquired pneumonia. The role of dual antibacterial therapy. Drugs 2005; 65: 1949-1971.
36. Consejo General de Colegios Oficiales de Farmacéuticos. Catálogo de especialidades farmacéuticas. Madrid. 2006.